Trial Profile

A phase 2 trial of VIM-0423 in Parkinson's disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 30 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs VIM 0423 (Primary)
Indications Parkinson's disease
Focus Therapeutic Use

Most Recent Events

30 Mar 2026 New trial record
11 Mar 2026 According to Vima Therapeutics media release, this trial is expected to initiate in mid-2026 and topline data from this study is expected in 1H 2027.
11 Mar 2026 According to Vima Therapeutics media release, the company has procured a new sum of $40 million which brings Series A total to $100 million. This will enable the advancement of this trial along with another phase 2 trial in Dystonia.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com